Bcl-2 is widely known to be an antiapoptotic proto-oncogene involved in carcinogenesis and is currently assessed for its use as a therapeutic target for B cell non-Hodgkin’s lymphoma. Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.